(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.21%) $0.928
(0.35%) $10.88
(0.00%) $0.792
(-0.30%) $92.30
Live Chart Being Loaded With Signals
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders...
Stats | |
---|---|
Today's Volume | 19 621.00 |
Average Volume | 34 291.00 |
Market Cap | 8.88M |
EPS | €0 ( 2024-01-17 ) |
Next earnings date | ( €0 ) 2024-04-11 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -0.990 |
ATR14 | €0.0270 (2.35%) |
Volume Correlation
Theranexus SA Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Theranexus SA Correlation - Currency/Commodity
Theranexus SA Financials
Annual | 2022 |
Revenue: | €414 898 |
Gross Profit: | €82 898.00 (19.98 %) |
EPS: | €-1.240 |
Q2 | 2023 |
Revenue: | €244 331 |
Gross Profit: | €76 331.00 (31.24 %) |
EPS: | €-0.680 |
Q4 | 2022 |
Revenue: | €2 245.00 |
Gross Profit: | €-163 755 (-7 294.21 %) |
EPS: | €-0.610 |
Q2 | 2022 |
Revenue: | €412 653 |
Gross Profit: | €246 653 (59.77 %) |
EPS: | €-0.620 |
Financial Reports:
No articles found.
Theranexus SA
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators